Stellar Announces Launch of Uracyst in the United Kingdom
Stellar Pharmaceuticals announced that sales of Uracyst have commenced in the United Kingdom through G. Pohl-Boskamp GmbH, Stellar's exclusive Pan-European licensee for this product. Stellar expects to realize sales royalties beginning this month. Uracyst is formulated to treat interstitial cystitis ("IC"), an inflammatory disease of the urinary wall whose most common symptom is the need to urgently and frequently urinate. There is no known cure for IC, nor is there a dominant treatment in the market.